RESUMEN

BACKGROUND: Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare disease characterized by pulmonary radiological alterations, peripheral eosinophilia, and demonstrated pulmonary eosinophilia. Oral steroids (OSs) are the standard management, but relapses occur in up to 50% of patients during the decrease or suspension of steroids, usually requiring reinitiation of treatment, exposing patients to secondary events derived from the management. Management with monoclonal antibodies has been proposed in these cases to control the disease and limit the secondary effects. The objective is to describe the extent and type of evidence regarding the use of monoclonal antibodies for ICEP. METHODS: A panoramic review of the literature was performed. Observational and experimental studies of pediatric and adult populations that managed recurrent ICEP with monoclonal antibodies were included. Data search, selection, and extraction were performed by two independent reviewers. RESULTS: 937 studies were found. After applying the inclusion and exclusion criteria, 37 titles remained for the final analysis: a retrospective, observational, real-life study, two case series publications, and 34 case reports published in academic poster sessions and letters to the editor. In general, the use of monoclonal antibodies approved for severe asthma could be useful for the control of ICEP, since most of the results show a good response for clinical and radiological outcomes. Biological drugs seem to be a safer option for controlling relapses in ICEP, allowing lowering/suspension of OSs, and sometimes replacing them in patients intolerant to them, patients with significant comorbidities, and patients who have already developed adverse events. CONCLUSION: The extent of the evidence supporting management of ICEP with monoclonal antibodies against IL-5 and IgE (omalizumab) is limited, but it could be promising in patients who present frequent relapses, in cortico-dependent individuals, or in patients in whom the use of steroids is contraindicated. The extent of the evidence for management with dupilumab is more limited. Studies with better design and structure are needed to evaluate quality of life and outcomes during a clear follow-up period. To our knowledge, this is the first scoping review of the literature showing the extent of the evidence for the management of ICEP with monoclonal antibodies.

Asunto(s)

RESUMEN

Chronic eosinophilic pneumonia (CEP) is a rare disease of unknown cause characterized by alveolar and interstitial eosinophilic infiltration. The tomographic pattern is characterized by consolidations and peripherally distributed ground glass opacities in both upper lobes. Other findings are opacities in bands parallel to the pleura, thickening of the interlobular septa, migratory opacities, and mediastinal lymph nodes. We presented a case of a woman with CEP and described the most relevant clinical and radiological characteristics.

La neumonía eosinofílica crónica (NEC) es una enfermedad rara de causa desconocida caracterizada por infiltración eosinofílica alveolar e intersticial. El patrón tomográfico se caracteriza por consolidaciones y opacidades en vidrio esmerilado de distribución periférica en ambos lóbulos superiores. Otros hallazgos son las opacidades en bandas paralelas a la pleura, engrosamiento de septos interlobulillares, opacidades migratrices y adenomegalias mediastinales. Se presenta el caso de una mujer con NEC y se describen las características clínicas y radiológicas más relevantes.

Asunto(s)

RESUMEN

Resumen La estrongiloidiasis es una infección causada por el parásito Strongyloides stercoralis (SS) y se asocia con una alta mortalidad en pacientes inmunosuprimidos debido a una diseminación larvaria y síndrome de hiperinfección. El compromiso de la mucosa gástrica es raro, pero cuando se presenta se caracteriza por sangrado digestivo y emesis persistente. A continuación, se presenta el caso de un paciente de 27 años con síntomas gastrointestinales, antecedente de infección por el virus linfotrópico humano de células T tipo 1 (HTLV-1) y colitis ulcerativa, quien desarrolló síndrome de hiperinfección por SS. Se describe la presentación clínica, diagnóstico, tratamiento y complicaciones derivadas del cuadro infeccioso.

Abstract Strongyloidiasis is an infection caused by the parasite Strongyloides stercolaris (SS) and is associated with high mortality in immunosuppressed patients due to larval spread and hyperinfection syndrome. Gastric mucosal involvement is rare, but when it occurs, it is characterized by digestive bleeding and persistent emesis. The following is the case of a 27-year-old patient with gastrointestinal symptoms, a history of HTLV-1 infection and ulcerative colitis, who developed hyperinfection syndrome with SS. The clinical presentation, diagnosis, treatment and complications arising from the infectious disease are described.

Asunto(s)

RESUMEN

Drug reaction with eosinophilia and systemic symptoms is a rare and potentially fatal drug hypersensitivity reaction. Reactions include skin eruption, fever, hematologic abnormalities (eosinophilia or atypical lymphocytosis), enlarged lymph nodes, and/or organic involvement. The liver is the most commonly compromised organ. We present a case of drug reaction with eosinophilia and systemic symptoms associated with Naproxen intake in a young female patient with severe lung involvement. The patient's chest tomography highlights the presence of adenomegalies, pericardial and pleural effusion, peribroncovascular consolidations, and centrilobular nodules. After reviewing the literature few similar cases were found. The main radiological alterations in those cases included interstitial opacities attributed to pneumonitis. Therefore, this case study is considered an unusual case with atypical presentation of drug-induced eosinophilic lung disease.

RESUMEN

Las eosinofilias pulmonares constituyen un grupo variado de entidades cuyo nexo común es la inflamación eosinofílica que puede o no asociarse a eosinofilia periférica. En ese reporte describimos una forma atípica y no descripta de presentación como "pseudotumor pulmonar" que remitió con tratamiento corticoesteroideo.

Pulmonary eosinophilia are a varied group of entities sharing the eosinophilic inflammation that may or may not be associated with peripheral eosinophilia. This report describes an atypical, undescribed presentation, the "pulmonary pseudotumor" which showed regression with corticosteroid treatment.

Asunto(s)

RESUMEN

Chronic eosinophilic pneumonia (CEP) is uncommon and predominantly seen in women. More than 6% of eosinophils in peripheral blood and more than 25% in bronchoalveolar lavage are diagnostic criteria. Secondary causes of hypereosinophilic pneumonia must be ruled out. We report a 72-year-old non-smoker man presenting in the emergency room with a history of cough, fever, and moderate dyspnea. He was not taking any medication. A chest-X ray showed a left lower lobe (LLL) consolidation, and was started on broad-spectrum antibiotics with a presumptive diagnosis of pneumonia. There was no improvement after therapy. A chest CT scan showed increased LLL consolidation and new left upper lobe ground glass opacities as well as a moderate left pleural effusion. Flexible bronchoscopy was performed and bronchoalveolar lavage showed 95% eosinophils, and had negative cultures. No parasites were identified. Transbronchial biopsies demonstrated eosinophil accumulation in alveoli and interstitium and pleural fluid was composed by 85% eosinophils. With the diagnosis of CEP, systemic corticosteroids were used with favorable clinical and radiological response.

Asunto(s)

RESUMEN

OBJECTIVE: To evaluate the effect size of oral corticosteroid treatment on eosinophilic bronchitis in asthma, through systematic review and meta-analysis. METHODS: We systematically reviewed articles in the Medline, Cochrane Controlled Trials Register, EMBASE, and LILACS databases. We selected studies meeting the following criteria: comparing at least two groups or time points (prednisone vs. control, prednisone vs. another drug, or pre- vs. post-treatment with prednisone); and evaluating parameters before and after prednisone use, including values for sputum eosinophils, sputum eosinophil cationic protein (ECP), and sputum IL-5-with or without values for post-bronchodilator FEV1-with corresponding 95% CIs or with sufficient data for calculation. The independent variables were the use, dose, and duration of prednisone treatment. The outcomes evaluated were sputum eosinophils, IL-5, and ECP, as well as post-bronchodilator FEV1. RESULTS: The pooled analysis of the pre- vs. post-treatment data revealed a significant mean reduction in sputum eosinophils (↓8.18%; 95% CI: 7.69-8.67; p < 0.001), sputum IL-5 (↓83.64 pg/mL; 95% CI: 52.45-114.83; p < 0.001), and sputum ECP (↓267.60 µg/L; 95% CI: 244.57-290.63; p < 0.0001), as well as a significant mean increase in post-bronchodilator FEV1 (↑8.09%; 95% CI: 5.35-10.83; p < 0.001). CONCLUSIONS: In patients with moderate-to-severe eosinophilic bronchitis, treatment with prednisone caused a significant reduction in sputum eosinophil counts, as well as in the sputum levels of IL-5 and ECP. This reduction in the inflammatory response was accompanied by a significant increase in post-bronchodilator FEV1. .

OBJETIVO: Avaliar o tamanho do efeito do tratamento com prednisona oral na bronquite eosinofílica na asma por meio de revisão sistemática e meta-análise. MÉTODOS: Revisão sistemática de artigos nas bases de dados do Medline, Cochrane Controlled Trials Register, EMBASE e LILACS. Foram selecionados estudos que preencheram os seguintes critérios: comparar ao menos dois grupos ou dois momentos (prednisona vs. controle, prednisona vs. outra droga ou pré vs. pós-tratamento com prednisona) e avaliar parâmetros antes e depois do uso de prednisona, incluindo eosinófilos, proteína catiônica eosinofílica (PCE) e IL-5 no escarro - com ou sem valores de VEF1 pós-broncodilatador - com os IC95% correspondentes ou com dados suficientes para calculá-los. As variáveis independentes foram uso e dose de prednisona e duração do tratamento. Os desfechos avaliados foram eosinófilos, IL-5 e PCE no escarro, bem como VEF1 pós-broncodilatador. RESULTADOS: A análise conjunta dos dados de pré e pós-tratamento revelou uma redução significativa nas médias de eosinófilos no escarro (↓8,18%; IC95%: 7,69-8,67; p < 0,001), IL-5 no escarro (↓83,64 pg/mL; IC95%: 52,45-114,83; p < 0,001), PCE no escarro (↓267,60 μg/L; IC95%: 244,57-290,93; p < 0,001), assim como um aumento significativo na média de VEF1 pós-broncodilatador (↑8,09%; IC95%: 5,35-10,83; p < 0,001). CONCLUSÕES: Em pacientes com bronquite eosinofílica de moderada a grave, o tratamento com prednisona determinou uma redução significativa nos níveis de eosinófilos no escarro, assim como nos níveis de IL-5 e PCE no escarro. Essa redução na resposta inflamatória foi acompanhada de um aumento significativo do VEF1 pós-broncodilatador. .

Asunto(s)

RESUMEN

As doenças hipersensíveis do tipo imediato podem ocorrer em um ou mais tecidos-alvo. Nessas enfermidades,em especial as hipersensibilidades do tipo I, os eosinófi los apresentam papel importante.A maioria dos eosinófi los migra para os tecidos, especialmente os de interface ambiental, como pulmões,trato digestório e pele. Todavia, em alguns casos, o processo infl amatório aliado a presençade um alérgeno inalado pode ocasionar uma resposta exacerbada imunológica no trato respiratório,induzindo o aumento do número de eosinófi los no parênquima pulmonar. A perpetuação resultaem alteração do padrão respiratório, como tosse, difi culdade respiratória, expectoração e descargamucopurulenta. No cão, as pneumopatias hipersensíveis eosinofílicas incluem a infi ltração pulmonarcom eosinófi los (IPE), eosinofi lia pulmonar (EP), pneumonia granulomatosa eosinofílica (PGE) ebroncopneumopatia eosinofílica (BPE). Nesse artigo apresenta-se uma revisão de literatura sobre aspneumopatias eosinofílicas, seguido de uma descrição de caso de BPE alergênica canina

Hypersensitivity diseases of the imediate type may occur in one or more target tissues. In these disorders,specially the type I hipersensitivities, eosinophils have important role. Most of the eosinophilsmigrate to tissues, specially the enviromental interface, like lungs, digestory tract and skin. However,in some cases, the infl ammatory process together with the presence of inhaled allergen may causean exacerbated immunological response in the respiratory tract, leading to increased numbers of eosinophilsin lung parenchyma. The perpetuation results in respiratory pattern alteration as cough,respiratory distress, expetoration and mucopurulent discharge. In the dog, the eosinophilic hipersensitivitypneumopathies include the eosinophil pulmonary infi ltration (EPI), pulmonary eosinophilia(PE), eosinophilic granulomatous pneumonia (EGP) and eosinophilic bronchopneumopathy (EBP).This article presents eosinophilic lung diseases literature review, followed by a case report of a canineallergenic EBP

Asunto(s)

RESUMEN

As doenças hipersensíveis do tipo imediato podem ocorrer em um ou mais tecidos-alvo. Nessas enfermidades,em especial as hipersensibilidades do tipo I, os eosinófi los apresentam papel importante.A maioria dos eosinófi los migra para os tecidos, especialmente os de interface ambiental, como pulmões,trato digestório e pele. Todavia, em alguns casos, o processo infl amatório aliado a presençade um alérgeno inalado pode ocasionar uma resposta exacerbada imunológica no trato respiratório,induzindo o aumento do número de eosinófi los no parênquima pulmonar. A perpetuação resultaem alteração do padrão respiratório, como tosse, difi culdade respiratória, expectoração e descargamucopurulenta. No cão, as pneumopatias hipersensíveis eosinofílicas incluem a infi ltração pulmonarcom eosinófi los (IPE), eosinofi lia pulmonar (EP), pneumonia granulomatosa eosinofílica (PGE) ebroncopneumopatia eosinofílica (BPE). Nesse artigo apresenta-se uma revisão de literatura sobre aspneumopatias eosinofílicas, seguido de uma descrição de caso de BPE alergênica canina(AU)

Hypersensitivity diseases of the imediate type may occur in one or more target tissues. In these disorders,specially the type I hipersensitivities, eosinophils have important role. Most of the eosinophilsmigrate to tissues, specially the enviromental interface, like lungs, digestory tract and skin. However,in some cases, the infl ammatory process together with the presence of inhaled allergen may causean exacerbated immunological response in the respiratory tract, leading to increased numbers of eosinophilsin lung parenchyma. The perpetuation results in respiratory pattern alteration as cough,respiratory distress, expetoration and mucopurulent discharge. In the dog, the eosinophilic hipersensitivitypneumopathies include the eosinophil pulmonary infi ltration (EPI), pulmonary eosinophilia(PE), eosinophilic granulomatous pneumonia (EGP) and eosinophilic bronchopneumopathy (EBP).This article presents eosinophilic lung diseases literature review, followed by a case report of a canineallergenic EBP(AU)

Asunto(s)

RESUMEN

As formas de eosinofilia pulmonar constituem um grupo heterogêneo definido pela presença de um ou dois critérios: infiltrado pulmonar com eosinofilia sanguínea e/ou eosinofilia tissular caracterizada por eosinófilos demonstrados na biópsia pulmonar ou no lavado broncoalveolar. Embora o infiltrado inflamatório seja composto de macrófagos, linfócitos, neutrófilos e eosinófilos, a presença de eosinofilia é um marcador importante para o diagnóstico e tratamento. A apresentação clínica e radiológica pode revelar eosinofilia pulmonar simples, pneumonia eosinofílica crônica, pneumonia eosinofílica aguda, aspergilose broncopulmonar alérgica e eosinofilia pulmonar associada à doença sistêmica, como na síndrome de Churg-Strauss e na síndrome hipereosinofílica. A asma está frequentemente associada, podendo ser um pré-requisito, como na aspergilose broncopulmonar alérgica e na síndrome de Churg-Strauss. Nas doenças com acometimento sistêmico, a pele, o coração e o sistema nervoso são os órgãos mais comprometidos. A apresentação radiológica pode ser considerada como típica, ou pelo menos sugestiva, para três formas de eosinofilia pulmonar: pneumonia eosinofílica crônica, aspergilose broncopulmonar alérgica e pneumonia eosinofílica aguda. A etiologia da eosinofilia pulmonar pode ser de causa primária (idiopática) ou secundária, compreendendo causas conhecidas, como drogas, parasitas, infecções por fungos e micobactérias, irradiação e toxinas. A eosinofilia pulmonar pode também estar associada a doenças pulmonares difusas, doenças do tecido conectivo e neoplasias.

Pulmonary eosinophilia comprises a heterogeneous group of diseases defined by eosinophilia in pulmonary infiltrates (bronchoalveolar lavage fluid) or in tissue (lung biopsy specimens). Although the inflammatory infiltrate is composed of macrophages, lymphocytes, neutrophils and eosinophils, eosinophilia is an important marker for the diagnosis and treatment. Clinical and radiological presentations can include simple pulmonary eosinophilia, chronic eosinophilic pneumonia, acute eosinophilic pneumonia, allergic bronchopulmonary aspergillosis and pulmonary eosinophilia associated with a systemic disease, such as in Churg-Strauss syndrome and hypereosinophilic syndrome. Asthma is frequently concomitant and can be a prerequisite, as in allergic bronchopulmonary aspergillosis and Churg-Strauss syndrome. In diseases with systemic involvement, the skin, the heart and the nervous system are the most affected organs. The radiological presentation can be typical, or at least suggestive, of one of three types of pulmonary eosinophilia: chronic eosinophilic pneumonia, acute eosinophilic pneumonia and allergic bronchopulmonary aspergillosis. The etiology of pulmonary eosinophilia can be either primary (idiopathic) or secondary, due to known causes, such as drugs, parasites, fungal infection, mycobacterial infection, irradiation and toxins. Pulmonary eosinophilia can be also associated with diffuse lung diseases, connective tissue diseases and neoplasia.

Asunto(s)

RESUMEN

Os autores relatam o caso de uma paciente com estenose de uretra que desenvolveu pneumonia eosinofílica crônica secundária ao uso prolongado de nitrofurantoína como profilaxia para infecção urinária de repetição. A paciente havia sido submetida a uma biópsia pulmonar a céu aberto. É dada ênfase aos achados da tomografia computadorizada de alta resolução do tórax, já que, embora as alterações pulmonares associadas à toxicidade da nitrofurantoína geralmente sejam basais e bilaterais, no caso aqui descrito, as lesões de natureza interstício-alveolares situaram-se nas regiões subpleurais dos lobos superiores. Esses achados, por si só, são muito sugestivos de pneumonia eosinofílica crônica. O diagnóstico foi confirmado por meio da revisão da biópsia.

The authors report the case of a female patient who developed chronic eosinophilic pneumonia secondary to long-term use of nitrofurantoin for prophylaxis of recurrent urinary tract infections due to urethral stenosis. On high-resolution computed tomography scans, the pulmonary reaction to nitrofurantoin most commonly manifests as an interstitial-alveolar pattern in both lung bases. However, in this case, the alterations were most pronounced in the periphery of the upper lobes. In itself, this tomographic profile is strongly indicative of chronic eosinophilic pneumonia. The patient had previously been submitted to an open lung biopsy. The diagnosis of chronic eosinophilic pneumonia was confirmed through a review of the biopsy.

Asunto(s)